• Je něco špatně v tomto záznamu ?

Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data

P. Szturz, M. Budíková, JB. Vermorken, I. Horová, B. Gál, E. Raymond, A. de Gramont, S. Faivre,

. 2017 ; 74 (-) : 68-76. [pub] 20170927

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, metaanalýza, přehledy, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033592

OBJECTIVES: The hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) ligand/receptor axis has been implicated in pathogenesis of malignant diseases including squamous cell carcinoma of the head and neck (SCCHN). Overexpression of c-MET has been reported as a common molecular abnormality in SCCHN, although its prognostic and predictive value remains to be validated. METHODS: We systematically searched literature for studies evaluating c-MET expression on immunohistochemistry in newly diagnosed, non-metastatic SCCHN. The c-MET expressing cases were classified into three categories according to predefined cut-off values for positivity. Our aim was to assess the prevalence of c-MET expression and its relationship with selected clinicopathological variables. RESULTS: Twenty-eight studies with 2019 cases were included. Relative frequencies of c-MET expression above cut-off levels I, II, and III were 81.8%, 63.8%, and 46.2%, respectively. Differences between these three values were statistically significant (p<1.0×10-6). Above cut-off level II, c-MET positivity was associated with worse overall survival (p=4.0×10-6), positive nodal status (p=1.0×10-4), higher disease stage (p=7.0×10-4), older age (p=2.1×10-3), disease recurrence (p=2.0×10-2), and primary tumour localization in the oral cavity (p=2.3×10-2). Above cut-off level III, c-MET positivity was associated with worse disease-free or progression-free survival (p=9.0×10-6), p16 negativity (p=2.4×10-4), worse overall survival (p=4.0×10-4), positive epidermal growth factor receptor (EGFR) status (p=7.2×10-4), and larger primary tumours (p=4.6×10-3). CONCLUSION: In SCCHN, immunohistochemical overexpression of c-MET above cut-off levels III and particularly II was associated with inferior survival outcomes and advanced disease. Moreover, it represents a promising predictive biomarker for c-MET targeting, yet the optimal scoring method remains to be defined.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033592
003      
CZ-PrNML
005      
20181015122747.0
007      
ta
008      
181008s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.oraloncology.2017.09.009 $2 doi
035    __
$a (PubMed)29103754
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Szturz, Petr $u Department of Internal Medicine, Hematology, and Oncology, University Hospital Brno, Brno, Czech Republic; School of Medicine, Masaryk University, Brno, Czech Republic. Electronic address: szturz@gmail.com.
245    10
$a Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data / $c P. Szturz, M. Budíková, JB. Vermorken, I. Horová, B. Gál, E. Raymond, A. de Gramont, S. Faivre,
520    9_
$a OBJECTIVES: The hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) ligand/receptor axis has been implicated in pathogenesis of malignant diseases including squamous cell carcinoma of the head and neck (SCCHN). Overexpression of c-MET has been reported as a common molecular abnormality in SCCHN, although its prognostic and predictive value remains to be validated. METHODS: We systematically searched literature for studies evaluating c-MET expression on immunohistochemistry in newly diagnosed, non-metastatic SCCHN. The c-MET expressing cases were classified into three categories according to predefined cut-off values for positivity. Our aim was to assess the prevalence of c-MET expression and its relationship with selected clinicopathological variables. RESULTS: Twenty-eight studies with 2019 cases were included. Relative frequencies of c-MET expression above cut-off levels I, II, and III were 81.8%, 63.8%, and 46.2%, respectively. Differences between these three values were statistically significant (p<1.0×10-6). Above cut-off level II, c-MET positivity was associated with worse overall survival (p=4.0×10-6), positive nodal status (p=1.0×10-4), higher disease stage (p=7.0×10-4), older age (p=2.1×10-3), disease recurrence (p=2.0×10-2), and primary tumour localization in the oral cavity (p=2.3×10-2). Above cut-off level III, c-MET positivity was associated with worse disease-free or progression-free survival (p=9.0×10-6), p16 negativity (p=2.4×10-4), worse overall survival (p=4.0×10-4), positive epidermal growth factor receptor (EGFR) status (p=7.2×10-4), and larger primary tumours (p=4.6×10-3). CONCLUSION: In SCCHN, immunohistochemical overexpression of c-MET above cut-off levels III and particularly II was associated with inferior survival outcomes and advanced disease. Moreover, it represents a promising predictive biomarker for c-MET targeting, yet the optimal scoring method remains to be defined.
650    _2
$a spinocelulární karcinom $x genetika $x patologie $x patofyziologie $7 D002294
650    _2
$a epitelo-mezenchymální tranzice $7 D058750
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a nádory hlavy a krku $x genetika $x patologie $x patofyziologie $7 D006258
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
650    _2
$a protoonkogenní proteiny c-met $x genetika $x fyziologie $7 D019859
650    _2
$a analýza přežití $7 D016019
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a přehledy $7 D016454
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Budíková, Marie $u Department of Mathematics and Statistics, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Vermorken, Jan B $u Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
700    1_
$a Horová, Ivana $u Department of Mathematics and Statistics, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Gál, Břetislav $u School of Medicine, Masaryk University, Brno, Czech Republic; Department of Otorhinolaryngology and Head and Neck Surgery, St. Anne's Faculty Hospital Brno, Brno, Czech Republic.
700    1_
$a Raymond, Eric $u Department of Oncology, Hospital Paris Saint-Joseph, Paris, France.
700    1_
$a de Gramont, Armand $u AFR Oncology, Boulogne-Billancourt, France.
700    1_
$a Faivre, Sandrine $u Department of Oncology, Bichat-Beaujon University Hospital, Paris, France.
773    0_
$w MED00003631 $t Oral oncology $x 1879-0593 $g Roč. 74, č. - (2017), s. 68-76
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29103754 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181015123243 $b ABA008
999    __
$a ok $b bmc $g 1340217 $s 1030586
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 74 $c - $d 68-76 $e 20170927 $i 1879-0593 $m Oral oncology $n Oral Oncol $x MED00003631
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Možnosti archivace